Weight-loss programs to slow kidney cancer progression in small renal masses on active surveillance
Official title: Development and Analysis of Weight Loss Programs for Renal Cell Carcinoma Patients on Active Surveillance
Run by Roswell Park Cancer Institute · NCT07714018 · Data updated 2026-11-12
This study tests two weight-loss approaches, daily calorie restriction and 5:2 intermittent fasting, to see if they help people with small kidney tumors on active surveillance lose weight and potentially slow cancer progression.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Roswell Park Cancer Institute Academic / other |
| Locations | 1 site (Buffalo, New York) |
| Status | Recruiting |
| Started | November 1, 2026 |
| Main results expected | November 1, 2027 |
| Study ends | November 1, 2028 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT07714018 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (18+) with biopsy-confirmed RCC on active surveillance, BMI ≥ 25 kg/m^2, English-speaking, and no contraindicating medical conditions.
✕Probably not a fit
Patients with BMI < 25 kg/m^2, non-English speakers, or those with contraindicating medical conditions or recent weight-loss surgery may be less likely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial adapts two evidence-based weight-loss methods for patients with small renal masses undergoing active surveillance. Participants are assigned to a continuous energy-restriction plan or a 5:2 intermittent fasting plan, both with self-monitoring and feedback from clinicians. Primary goals are to assess feasibility and weight loss, while secondary goals explore effects on diet, body composition, tumor growth, and progression to invasive treatment. The study is conducted at Roswell Park Comprehensive Cancer Center with English-speaking adults who meet BMI and health criteria.
Why it matters
Potential benefit: If successful, participants may achieve meaningful weight loss and insights into whether a particular weight-loss approach supports better health and slower cancer progression.
How similar studies have gone: While weight-loss interventions have shown health benefits, this direct comparison for slowing progression of small renal masses is a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * English speaking * SRM patient with biopsy-confirmed RCC who are initiating or already on AS * Age 18 years or older * Body mass index (BMI) ≥ 25 kg/m\^2 * No medical problems that might contraindicate participation in a behavioral weight reduction program containing an exercise component * No weight loss medication in the past 3 months * Not pregnant or lactating * No more than 5% body weight loss in the past 3 months * No bariatric surgery in the last 10 years Exclusion Criteria: * Non-English speaking * Less than 18 years old * BMI \< 25 kg/m\^2 * Medical problems that might contraindicate participation in a behavioral weight reduction program containing an exercise component * On weight loss medication in the past 3 months * Pregnant or lactating * More than 5% body weight loss in the past 3 months * Bariatric surgery in the last 10 years * Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug * Unwilling or unable to follow protocol requirements * Received an investigational agent within 30 days prior to enrollment
Where it's running
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States Recruiting
Study contacts
- Principal investigator: Eric Kaufmann — Roswell Park Comprehensive Cancer Center
- Study coordinator: Ask Rpci
- Email: askroswell@roswellpark.org
- Phone: 1-800-767-9355
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Nectin-4 PET/CT imaging to differentiate renal tumors
This study tests a new PET tracer, 18F-N230A, to see if it helps distinguish renal cell carcinoma from renal pelvic urothelial carcinoma in adults.
-
Predicting Toripalimab Response in High-Risk Recurrent Renal Cell Carcinoma using MRD
This study tests whether measuring minimal residual disease after surgery can predict which high-risk RCC patients will benefit from adjuvant Toripalimab.
-
Safety and tolerability test of anti-CD70 T-cell therapy in advanced RCC
This study tests a CD70-targeted CAR-T cell therapy in adults with advanced or metastatic renal cell carcinoma to see if it is safe and tolerable and to identify a usable dose for future studies.
-
VMD-102 in liver cancer and other solid tumors
This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.
-
Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance
This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.
-
Laparoscopic versus open kidney removal: comparing outcomes and costs
This trial will test whether laparoscopic (keyhole) kidney removal or open surgery gives better outcomes and lower costs for people needing a nephrectomy for a nonfunctioning kidney or localized kidney cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.